• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by uniQure N.V.

    8/1/24 8:54:09 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QURE alert in real time by email
    S-8 1 tmb-20240730xs8.htm S-8

    As filed with the Securities and Exchange Commission on August 1, 2024

    ​

    Registration No. 333-

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    ​

    FORM S-8

    ​

    REGISTRATION STATEMENT UNDER

    THE SECURITIES ACT OF 1933

    ​

    UNIQURE N.V.

    (Exact Name of Registrant as Specified in its Charter)

    ​

    Netherlands

    N/A

    (State or Other Jurisdiction of Incorporation or
    Organization)

    (I.R.S. Employer Identification
    No.)

    Paasheuvelweg 25a,
    1105 BP Amsterdam, The Netherlands

    N/A

    (Address of Principal Executive Offices)

    (Zip Code)

    ​

    uniQure N.V. Amended and Restated 2014 Share Incentive Plan

    (Full Title of the Plan)

    ​

    Matthew Kapusta

    Chief Executive Officer

    113 Hartwell Avenue

    Lexington, MA 02421

    (Name and Address of Agent For Service)

    ​

    Tel: +1 339 970 7000

    (Telephone Number, Including Area Code, of Agent For Service)

    ​

    ​

    Copies to:

    ​

    Jeannette Potts

    Chief Legal Officer

    113 Hartwell Avenue

    Lexington, MA 02421

    +1 339 970 7000

    ​

    Timothy J. Corbett

    Benjamin Stein

    Morgan, Lewis & Bockius UK LLP

    Condor House, 5-10 St. Paul’s Churchyard

    London EC4M 8AL United Kingdom

    +44 20 3201 5690

    ​

    ​

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

    ​

    Large accelerated filer ☐

    Accelerated filer ☒

    Non-accelerated filer ☐

    Smaller reporting company ☐

     

    Emerging growth company ☐

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

    ​

    ​

    ​


    EXPLANATORY NOTE

    ​

    This Registration Statement on Form S-8 (this “Registration Statement”) is being filed by uniQure N.V. (the “Registrant”) solely for the purpose of registering an additional 1,500,000 ordinary shares, par value €0.05 per share, of the Registrant (the “Ordinary Shares”) to be offered to participants under the Registrant’s Amended and Restated 2014 Share Incentive Plan, which was originally adopted at the annual general meeting of the Registrant’s shareholders on January 9, 2014 and was subsequently amended or amended and restated, as applicable, as of June 10, 2015, June 15, 2016, June 13, 2018, June 16, 2021, November 15, 2023 and June 18, 2024 (as amended and restated to date, the “2014 Plan”).

    ​

    On April 11, 2024, an amendment to the 2014 Plan (in the form then in effect) was approved by the board of directors of the Registrant and was subsequently approved by the Registrant’s shareholders at its annual general meeting on June 18, 2024 to increase the number of Ordinary Shares reserved for issuance under the 2014 Plan by an additional 1,500,000 shares.

    ​

    The Ordinary Shares registered hereby are in addition to and of the same class as those on the Registrant’s registration statements on Form S-8 registering (i) 1,531,471 Ordinary Shares issuable under 2014 Plan previously filed with the Securities and Exchange Commission (the “Commission”) on August 6, 2014 (File No. 333-197887), (ii) 4,070,000 Ordinary Shares issuable under the 2014 Plan previously filed with the Commission on May 15, 2017 (File No. 333-218005), (iii) 3,000,000 Ordinary Shares issuable under the 2014 Plan previously filed with the Commission on June 14, 2018 (File No. 333-225629), (iv) 4,000,000 Ordinary Shares issuable under the 2014 Plan previously filed with the Commission on July 20, 2021 (File No. 333-258036) and (v) 1,750,000 Ordinary Shares issuable under the 2014 Plan previously filed with the Commission on February 28, 2024 (File No. 333-277439) (collectively, the “Previous Registration Statements”). In accordance with General Instruction E to Form S-8, the contents of the Previous Registration Statements and the contents incorporated by reference therein are hereby incorporated herein by reference and the information required by Part II is omitted, except as supplemented by the information set forth below.

    ​


    ​

    ​

    ​

    PART II

    ​

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    ​

    Item 3. Incorporation of Documents by Reference.

    ​

    The following documents are incorporated herein by reference:

    ​

    (a) The Registrant’s Annual Report on Form 10-K for fiscal year ended December 31, 2023 filed with the Commission on February 28, 2024;

    ​

    (b) The Registrant’s Quarterly Reports on Form 10-Q filed with the Commission on May 7, 2024 and August 1, 2024;

    ​

    (c) The information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023 from the Registrant's Definitive Proxy Statement on Schedule 14A, filed with the Commission on April 24, 2024;

    (d) The Registrant’s Current Reports on Form 8-K filed with the Commission on April 12, 2024, June 20, 2024, July 1, 2024, July 9, 2024 and July 23, 2024; and

    ​

    (c) The description of the securities contained in the Registrant’s registration statement on Form 8-A (Registration No. 001-36294) filed with the Commission on January 31, 2014, under the Securities Exchange Act of 1934, as amended (the “Exchange

    Act”), including any amendment or report filed for the purpose of updating such description.

    ​

    All documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to specific sections of such documents as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement.

    ​

    Item 8. Exhibits.

    ​

    A list of exhibits filed herewith is contained in the Exhibit Index that immediately precedes the signature page hereto and is incorporated herein by reference.

    ​

    ​

    ​


    EXHIBIT INDEX

    ​

    Number

        

    Description

    5.1*

     

    Opinion of Rutgers & Posch N.V., counsel to the Registrant

    23.1*

     

    Consent of Rutgers & Posch N.V. (included in Exhibit No. 5.1)

    23.2*

     

    Consent of KPMG Accountants N.V., Independent Registered Public Accounting Firm

    24.1*

     

    Power of attorney (included on the signature pages of this Registration Statement on Form S-8)

    99.1

    ​

    Amended and Restated 2014 Share Incentive Plan of the Registrant (incorporated by reference to Exhibit No. 10.1

    to the Registrant’s Current Report on Form 8-K filed on June 20, 2024 (File No. 001-36294))

    107*

     

    Filing Fee Table

    ​

    * Filed herewith.

    ​

    ​


    SIGNATURES

    ​

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Amsterdam, the Netherlands, on August 1, 2024.

    ​

    ​

    UNIQURE N.V.

    ​

     

     

    ​

    By:

    /s/ Matthew Kapusta

    ​

     

    Matthew Kapusta

    ​

     

    Chief Executive Officer

    ​

    ​

    ​

    ​


    POWER OF ATTORNEY AND SIGNATURES

    ​

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Matthew Kapusta and Christian Klemt, and each of them, as his or her true and lawful agent, proxy and attorney-in-fact, each acting alone, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to (i) act on, sign, and file with the SEC any and all amendments (including post-effective amendments) to this registration statement together with all schedules and exhibits thereto, (ii) act on, sign and file such certificates, instruments, agreements and other documents as may be necessary or appropriate in connection therewith, (iii) act on and file any supplement to any prospectus included in this registration statement or any such amendment or any subsequent registration statement filed pursuant to Rule 462(b) under the Securities Act and (iv) take any and all actions which may be necessary or appropriate to be done, as fully for all intents and purposes as he or she might or could do in person, hereby approving, ratifying and confirming all that such agent, proxy and attorney-in-fact or any of his substitutes may lawfully do or cause to be done by virtue thereof.

    ​

    Pursuant to the requirements of the Securities Act, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

    ​

    Signatures

        

    Title

        

    Date

    ​

    ​

    ​

    ​

    ​

    /s/ Matthew Kapusta

    ​

    Chief Executive Officer and Director

    ​

    August 1, 2024

    Matthew Kapusta

    ​

    (Principal Executive Officer)

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Christian Klemt

    ​

    Chief Financial Officer

    ​

    August 1, 2024

    Christian Klemt

    ​

    (Principal Financial Officer and Principal Accounting Officer)

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Madhavan Balachandran

    ​

    Director

    ​

    August 1, 2024

    Madhavan Balachandran

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Robert Gut

    ​

    Director

    ​

    August 1, 2024

    Robert Gut

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Rachelle Jacques

    ​

    Director

    ​

    August 1, 2024

    Rachelle Jacques

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Jack Kaye

    ​

    Director

    ​

    August 1, 2024

    Jack Kaye

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ David Meek

    ​

    Director

    ​

    August 1, 2024

    David Meek

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Leonard Post

    ​

    Director

    ​

    August 1, 2024

    Leonard Post

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Jeremy P. Springhorn

    ​

    Director

    ​

    August 1, 2024

    Jeremy P. Springhorn

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​


    AUTHORIZED UNITED STATES REPRESENTATIVE

    ​

    Pursuant to the requirement of the Securities Act of 1933, the undersigned, the duly authorized representative in the United States of the aforementioned Registrant, has signed this Registration Statement on August 1, 2024.

    ​

    UNIQURE, INC.

    ​

     

     

    ​

    By:

    /s/ Jeannette Potts

    ​

    Name: Jeannette Potts

    ​

    Title: Chief Legal Officer

    ​

    ​


    Get the next $QURE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QURE

    DatePrice TargetRatingAnalyst
    1/28/2026$31.00Equal Weight
    Barclays
    11/4/2025Outperform → Mkt Perform
    William Blair
    8/14/2025$30.00Neutral → Outperform
    Mizuho
    4/1/2025$38.00Buy
    Chardan Capital Markets
    12/10/2024Outperform → Strong Buy
    Raymond James
    10/10/2024$20.00Outperform
    Raymond James
    2/29/2024$8.00Buy → Neutral
    Goldman
    12/19/2023$52.00 → $10.00Buy → Neutral
    Mizuho
    More analyst ratings

    $QURE
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by uniQure N.V.

    SCHEDULE 13G - uniQure N.V. (0001590560) (Subject)

    2/9/26 8:10:32 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure N.V. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - uniQure N.V. (0001590560) (Filer)

    1/13/26 7:05:15 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by uniQure N.V.

    144 - uniQure N.V. (0001590560) (Subject)

    1/9/26 3:59:51 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QURE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gut Robert exercised 17,810 units of Ordinary Shares at a strike of $14.08 and sold $630,483 worth of Ordinary Shares (25,613 units at $24.62), decreasing direct ownership by 19% to 32,342 units (SEC Form 4)

    4 - uniQure N.V. (0001590560) (Issuer)

    1/14/26 4:26:27 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kaye Jack exercised 6,390 units of Ordinary Shares at a strike of $19.39 and sold $174,319 worth of Ordinary Shares (6,390 units at $27.28) (SEC Form 4)

    4 - uniQure N.V. (0001590560) (Issuer)

    1/12/26 4:21:22 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Gut Robert exercised 15,840 units of Ordinary Shares at a strike of $4.57 and sold $856,881 worth of Ordinary Shares (31,434 units at $27.26), decreasing direct ownership by 28% to 40,145 units (SEC Form 4)

    4 - uniQure N.V. (0001590560) (Issuer)

    11/10/25 4:54:55 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QURE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease

    ~ Supraphysiological expression of α-Gal A activity maintained for over a year in longest treated patient as of data cutoff date ~ ~ Stable Lyso-Gb3 levels maintained post-dosing, regardless of enzyme replacement therapy status across all cohorts ~ ~ Six of 11 patients have discontinued enzyme replacement therapy as of data cutoff date ~ LEXINGTON, Mass. and AMSTERDAM, Feb. 06, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced updated preliminary safety and exploratory efficacy data from 11 patients in its Phase I/IIa trial of AMT-191, an investigational AAV gene

    2/6/26 7:05:00 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure Announces Type A Meeting Scheduled with FDA

    LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced a Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled to discuss the Biologics License Application (BLA) data package to support accelerated approval of AMT-130, the Company's investigational gene therapy for the treatment of Huntington's disease. "We look forward to a constructive discussion with the FDA as we work toward a timely resolution regarding an accelerated approval pathway for AMT-130," said Matt Kapusta, chief executive officer at uni

    1/9/26 7:05:00 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    QURE Investigation: Investors Encouraged to Contact Kirby McInerney LLP

    The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of uniQure N.V. ("uniQure" or the "Company") (NASDAQ:QURE) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On November 3, 2025, uniQure disclosed that the Company "believes that the FDA currently no longer agrees that data from the Phase I/II studies of AMT-130 in comparison to an external control, as per the prespecified protocols and statistical analysis plans shared with the FDA in advance of the analyses, may be adequate to provide th

    1/5/26 6:00:00 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QURE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on uniQure with a new price target

    Barclays initiated coverage of uniQure with a rating of Equal Weight and set a new price target of $31.00

    1/28/26 7:20:10 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure downgraded by William Blair

    William Blair downgraded uniQure from Outperform to Mkt Perform

    11/4/25 7:43:29 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure upgraded by Mizuho with a new price target

    Mizuho upgraded uniQure from Neutral to Outperform and set a new price target of $30.00

    8/14/25 8:07:02 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QURE
    Leadership Updates

    Live Leadership Updates

    View All

    uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer

    ~ Proven biotech executive to lead commercialization of AMT-130 in Huntington's disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Kylie O'Keefe as Chief Customer and Strategy Officer, effective June 6, 2025. In this role, Ms. O'Keefe will lead the development and execution of uniQure's global commercialization strategy for AMT-130, the Company's investigational gene therapy for the treatment of Huntington's disease. Her responsibilities include all commercial functions and medical affairs. Ms. O'K

    6/11/25 8:00:00 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

    NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15. She succeeds Alan Holmer, who will remain on the Board. "We thank Alan for his over ten years of dedicated service as founding Chair of the Corbus Board," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "Rachelle is a seasoned biopharmaceutical executive, and we have greatly benefitted from her innovative and strategic thinking as a Board member.  We look forward to following her vision and continued leadership as we

    5/19/25 8:00:00 AM ET
    $AKTX
    $CRBP
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure Announces Leadership Addition to Support Advancement of Clinical Programs

    LEXINGTON, Mass. and AMSTERDAM, June 26, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Walid Abi-Saab, M.D., as Chief Medical Officer, effective immediately. He will report to Matt Kapusta, Chief Executive Officer of uniQure, and will be based in the Company's Basel, Switzerland office. Dr. Abi-Saab will be responsible for leading all clinical research and development, regulatory affairs, medical affairs, and program management at uniQure. With Dr. Abi-Saab's appointment, Dr. Ricardo Dolmetsch becomes President and Chief Scientific Officer. He

    6/26/23 7:11:42 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QURE
    Financials

    Live finance-specific insights

    View All

    uniQure to Announce Third Quarter 2025 Financial Results

    LEXINGTON, Mass. and AMSTERDAM, Nov. 06, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report third quarter 2025 financial results before market open on Monday, November 10, 2025. Management will then host a conference call at 8:30 a.m. ET. The event will be webcast under the Events & Presentations section of uniQure's website at https://www.uniqure.com/investors-media/events-presentations, and following the event a replay will be archived for 90 days. Analysts wishing to participate in the question and answer session should access the live call by dialing (646) 307-1963 or

    11/6/25 7:05:00 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington's Disease

    ~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a propensity score-matched external control ~ ~ High-dose AMT-130 also demonstrated statistically significant slowing of disease progression as measured by TFC, a key secondary endpoint, and favorable trends across additional clinical measures ~ ~ Mean cerebrospinal fluid NfL levels were below baseline at 36 months ~ ~ AMT-130 continued to be generally well-tolerated with a manageable safety profile ~ ~ uniQure plans to submit a BLA in the first quarter of 2026, with anticipated U.S. launch later that year, pending approval ~

    9/24/25 7:05:00 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

    ~ Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of 2026; ~ Company expects to present AMT-130 topline three-year data in September 2025 ~ ~ Presented case study from first participant treated with AMT-260 for refractory mesial temporal lobe epilepsy showing 92% seizure reduction with no serious adverse events through first five months of follow up ~ ~ Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer ~ ~ Cash, cash equivalents and current investment securities of approximately $

    7/29/25 7:05:00 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QURE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by uniQure N.V.

    SC 13G/A - uniQure N.V. (0001590560) (Subject)

    11/14/24 12:01:42 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by uniQure N.V.

    SC 13G/A - uniQure N.V. (0001590560) (Subject)

    11/13/24 4:05:14 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by uniQure N.V.

    SC 13G/A - uniQure N.V. (0001590560) (Subject)

    10/25/24 9:48:27 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care